Investigational New Drugs 1992-Nov
Phase II trial of merbarone in soft tissue sarcoma. A Southwest Oncology Group study.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Länken sparas på Urklipp
Nyckelord
Abstrakt
Thirty-seven patients with advanced soft tissue sarcoma were treated with merbarone utilizing a daily intravenous schedule for five days. Only one partial response was observed in the thirty-three evaluable patients. The major toxicities were renal, with elevation of creatinine and/or proteinuria, and gastrointestinal, with mild to moderate nausea and vomiting. Merbarone in this dose and schedule has minimal activity in soft tissue sarcoma.